HB1947, the TREAT PTSD Act, would require the Department of Veterans Affairs and the Department of Defense to furnish stellate ganglion block treatment to eligible veterans and eligible members of the Armed Forces who have been diagnosed with post-traumatic stress disorder (PTSD) and who choose the procedure after being informed of its risks and benefits by a qualified health care provider. The bill applies to veterans enrolled in the VA patient enrollment system and to active-duty or reserve-component service members enrolled in TRICARE or a Department-administered TRICARE program. It allows the treatment to be provided either at a VA or DoD medical facility or through approved outside providers.
The bill also directs VA and DoD to update their joint PTSD clinical practice guideline within 180 days of enactment so that it reflects stellate ganglion block as a therapy option and identifies clinical indicators and contraindicators for its use. The amendments to title 38 and title 10 would take effect 180 days after enactment, giving the departments time to implement the new coverage and guidance requirements. In practical terms, the bill would add a specific PTSD treatment to federal veterans and military health care law and could expand access to a procedure that is not currently mandated by statute.
The available legislative context shows no recorded votes and no committee transcript, so there is no documented floor debate or formal hearing record in the materials provided. The bill was referred to the House Committee on Armed Services and the Committee on Veterans’ Affairs, and later to the Subcommittee on Health, suggesting it is being considered primarily as a health-care policy measure for veterans and service members. Overall, the bill appears to have been introduced as a targeted treatment-access proposal rather than a broad overhaul of PTSD policy.
Because there is no discussion transcript, sentiment must be inferred from the bill’s structure and sponsorship rather than from explicit debate. The bill’s sponsors frame stellate ganglion block as an emerging and accessible therapy, indicating support for expanding treatment options for PTSD. The main likely point of contention is whether the federal government should be required to cover and operationalize a procedure that may still be viewed by some as an emerging or not yet universally established PTSD treatment, including questions about clinical evidence, safety, provider availability, and cost. Another possible issue is whether mandatory coverage should be limited to patients who elect the treatment after informed consent, as the bill provides.
Impact
The bill would amend title 38 of the U.S. Code to require VA to furnish stellate ganglion block to qualifying veterans with PTSD, and amend title 10 to require DoD to furnish the same treatment to qualifying service members with PTSD. It would also require VA and DoD to revise their joint PTSD clinical practice guideline to include the therapy and related clinical criteria, and it would take effect 180 days after enactment. The measure would therefore create a new statutory entitlement or coverage requirement for this specific procedure within federal veterans and military health systems.
Sentiment
No committee transcript or vote record is provided, so there is no direct evidence of bipartisan support or opposition in the materials. The bill’s title and text suggest a generally favorable posture toward expanding PTSD treatment options for veterans and service members, with the sponsors presenting the procedure as an accessible emerging therapy. The absence of recorded opposition in the supplied context leaves sentiment best characterized as supportive but not yet tested in committee or on the floor.
Contention
The likely areas of contention are the medical evidence base for stellate ganglion block, whether it should be mandated as a covered treatment for PTSD, and how broadly it should be made available through VA, DoD, and TRICARE networks. Skeptics may question whether the therapy is sufficiently established, whether it should be included in federal clinical guidelines, and what implementation and cost implications would follow. Supporters are likely to emphasize expanded access, patient choice, and potential relief for veterans and service members with PTSD.
Urging the Congress of the United States to expand post-traumatic stress disorder treatment for veterans and service members by authorizing stellate ganglion block therapy through passage of H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act.
Urging the Congress of the United States to pass H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act or similar legislation dealing with stellate ganglion block therapy to veterans and members of the armed forces of the United States with post-traumatic stress disorder, during the 119th United States Congress.
Requires Adjutant General of DMVA create program for veterans to receive evaluation and treatment for PTSD, total brain injury, or traumatic brain injury.
TBI and PTSD Treatment Act This bill requires the Department of Veterans Affairs to furnish hyperbaric oxygen therapy through a provider authorized by the Veterans Community Care Program to veterans who have a traumatic brain injury or post-traumatic stress disorder.
TBI and PTSD Treatment Act This bill requires the Department of Veterans Affairs to furnish hyperbaric oxygen therapy through a provider authorized by the Veterans Community Care Program to veterans who have a traumatic brain injury or post-traumatic stress disorder.
Urging the Congress of the United States to expand post-traumatic stress disorder treatment for veterans and service members by authorizing stellate ganglion block therapy through passage of H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act.
Urging the Congress of the United States to pass H.R. 1947, the Treatment and Relief through Emerging and Accessible Therapy for PTSD Act or similar legislation dealing with stellate ganglion block therapy to veterans and members of the armed forces of the United States with post-traumatic stress disorder, during the 119th United States Congress.